AGY Stock Overview
A commercial biotechnology company, engages in the research and development of allergy treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.053 |
| 52 Week High | UK£0.063 |
| 52 Week Low | UK£0.017 |
| Beta | 1.35 |
| 11 Month Change | 8.61% |
| 3 Month Change | 12.77% |
| 1 Year Change | 194.44% |
| 33 Year Change | -85.07% |
| 5 Year Change | -50.00% |
| Change since IPO | -92.89% |
Recent News & Updates
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward
Nov 09
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet
Sep 12Recent updates
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward
Nov 09Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet
Sep 12Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up
May 21Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Dec 18Shareholder Returns
| AGY | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -4.3% | -2.2% | -0.3% |
| 1Y | 194.4% | -3.2% | 6.1% |
Return vs Industry: AGY exceeded the UK Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: AGY exceeded the UK Market which returned 5.6% over the past year.
Price Volatility
| AGY volatility | |
|---|---|
| AGY Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AGY's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGY's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 612 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut.
Allergy Therapeutics plc Fundamentals Summary
| AGY fundamental statistics | |
|---|---|
| Market cap | UK£253.14m |
| Earnings (TTM) | -UK£40.22m |
| Revenue (TTM) | UK£55.20m |
4.6x
P/S Ratio-6.3x
P/E RatioIs AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGY income statement (TTM) | |
|---|---|
| Revenue | UK£55.20m |
| Cost of Revenue | UK£25.46m |
| Gross Profit | UK£29.74m |
| Other Expenses | UK£69.95m |
| Earnings | -UK£40.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0084 |
| Gross Margin | 53.87% |
| Net Profit Margin | -72.86% |
| Debt/Equity Ratio | 622.8% |
How did AGY perform over the long term?
See historical performance and comparison